SUBSCRIBE
SUBSCRIBE

Ultragenyx Pharmaceutical Inc.

NEWS
Deals
Novartis Buys Rare Drug Voucher for $130M From Ultragenyx
Ultragenyx CEO Emil Kakkis said the sale of the PRV will provide the company with an “important source of non-dilutive capital” that will be used to advance the company’s pipeline of rare and ultra-rare therapies.
December 18, 2017
 · 
2 min read
 · 
Alex Keown
Drug Development
Ultragenyx Stock Booms After Burosumab Continues to Impress in Phase III Study
Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.
December 4, 2017
 · 
3 min read
 · 
Alex Keown
Business
Does Genentech Have a New Mega-Blockbuster?
Genentech’s Hemlibra just got approved but is expected to bring in around $2 billion in peak sales.
November 27, 2017
 · 
1 min read
 · 
Karl Thiel
3 Biotechs That Got Huge Boosts From Spark's FDA P
Policy
6 Biotechs Facing Make-or-Break FDA PDUFA Catalysts in November
Here’s a closer look at six drugs facing FDA decisions in November.
October 31, 2017
 · 
2 min read
 · 
Mark Terry
Proteostasis and Roche Diagnostics Ink Huge Space in New Boston Hub
Deals
Bay Area’s Ultragenyx Swoops in With $138 Million Bid for Almost-Sold Dimension Therapeutics
September 18, 2017
 · 
3 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Bay Area’s Ultragenyx Tanks as Seizure Drug Flunks Phase II Test
March 23, 2017
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Bio NC
10 Biotech Stocks that Could Blow Up in Q3
July 6, 2016
 · 
3 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Biotech Bay
Nine Bay Area Biotechs Vie to be the “Next Genentech”
May 24, 2016
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Arcturus Therapeutics Stands to Collect Up to $1.66 Billion from Rare Disease Pact with Ultragenyx
October 29, 2015
 · 
3 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 23, 2026
January 26, 2026
 · 
1 min read
Press Releases
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
January 12, 2026
 · 
7 min read
Press Releases
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
 · 
1 min read
Press Releases
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
December 30, 2025
 · 
7 min read
Press Releases
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
 · 
8 min read
Press Releases
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
December 29, 2025
 · 
7 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 19, 2025
December 22, 2025
 · 
1 min read
Press Releases
Ultragenyx to Participate in Investor Conferences in December 2025
November 25, 2025
 · 
1 min read
Press Releases
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - November 21, 2025
November 24, 2025
 · 
1 min read
Press Releases
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
November 4, 2025
 · 
13 min read
Load More